Thyrocare Technologies Ltd
Thyrocare Technologies is engaged in the business of healthcare industry and is involved in providing quality diagnostic services at affordable costs to patients, laboratories and hospitals in India.
- Market Cap ₹ 8,727 Cr.
- Current Price ₹ 548
- High / Low ₹ 662 / 343
- Stock P/E 48.3
- Book Value ₹ 36.8
- Dividend Yield 1.70 %
- ROCE 35.4 %
- ROE 28.4 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 131%
Cons
- Stock is trading at 14.9 times its book value
- Promoters have pledged 100% of their holding.
- Promoter holding has decreased over last 3 years: -10.2%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 183 | 241 | 304 | 356 | 403 | 434 | 495 | 589 | 527 | 572 | 687 | 829 | 876 | |
| 110 | 147 | 189 | 212 | 249 | 261 | 323 | 353 | 403 | 432 | 498 | 566 | 594 | |
| Operating Profit | 73 | 94 | 115 | 145 | 154 | 174 | 171 | 236 | 123 | 140 | 190 | 263 | 282 |
| OPM % | 40% | 39% | 38% | 41% | 38% | 40% | 35% | 40% | 23% | 24% | 28% | 32% | 32% |
| 8 | 7 | -15 | 21 | 11 | 1 | 12 | 29 | 9 | 9 | 15 | 12 | 12 | |
| Interest | 0 | 1 | 0 | 0 | 1 | 2 | 1 | 3 | 5 | 6 | 4 | 4 | 3 |
| Depreciation | 13 | 18 | 18 | 20 | 26 | 32 | 30 | 34 | 39 | 47 | 55 | 59 | 60 |
| Profit before tax | 68 | 82 | 82 | 145 | 138 | 140 | 152 | 228 | 89 | 96 | 145 | 213 | 231 |
| Tax % | 35% | 37% | 48% | 36% | 38% | 37% | 26% | 23% | 27% | 28% | 38% | 24% | |
| 44 | 52 | 43 | 93 | 85 | 88 | 113 | 176 | 64 | 69 | 91 | 163 | 176 | |
| EPS in Rs | 2.98 | 3.21 | 2.66 | 5.79 | 5.38 | 5.58 | 7.13 | 11.10 | 4.06 | 4.45 | 5.76 | 10.24 | 11.08 |
| Dividend Payout % | 171% | 104% | 125% | 58% | 124% | 30% | 117% | 45% | 148% | 135% | 122% | 137% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 11% |
| 3 Years: | 16% |
| TTM: | 21% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 8% |
| 3 Years: | 36% |
| TTM: | 70% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 7% |
| 3 Years: | 43% |
| 1 Year: | 40% |
| Return on Equity | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | 20% |
| 3 Years: | 20% |
| Last Year: | 28% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 51 | 54 | 54 | 54 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 159 |
| Reserves | 226 | 312 | 354 | 390 | 382 | 314 | 374 | 474 | 481 | 474 | 494 | 426 |
| 0 | 0 | 0 | 0 | 2 | 12 | 8 | 21 | 23 | 42 | 25 | 51 | |
| 53 | 44 | 30 | 36 | 37 | 90 | 106 | 60 | 74 | 75 | 121 | 111 | |
| Total Liabilities | 329 | 410 | 438 | 479 | 475 | 469 | 541 | 607 | 632 | 644 | 693 | 747 |
| 196 | 259 | 259 | 299 | 294 | 269 | 253 | 285 | 294 | 306 | 297 | 317 | |
| CWIP | 6 | 1 | 17 | 0 | 1 | 5 | 8 | 3 | 2 | 3 | 14 | 3 |
| Investments | 86 | 93 | 104 | 120 | 95 | 90 | 126 | 146 | 144 | 162 | 162 | 177 |
| 42 | 56 | 58 | 60 | 84 | 105 | 154 | 173 | 192 | 173 | 220 | 250 | |
| Total Assets | 329 | 410 | 438 | 479 | 475 | 469 | 541 | 607 | 632 | 644 | 693 | 747 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 34 | 68 | 90 | 107 | 100 | 168 | 115 | 113 | 129 | 168 | 191 | 213 | |
| -18 | -18 | -42 | -43 | -12 | 1 | -49 | -24 | -39 | -91 | -53 | -23 | |
| -23 | -45 | -49 | -64 | -94 | -165 | -62 | -89 | -86 | -85 | -130 | -170 | |
| Net Cash Flow | -6 | 5 | -0 | -0 | -5 | 4 | 4 | 0 | 4 | -8 | 8 | 21 |
| Free Cash Flow | 25 | 53 | 53 | 63 | 61 | 158 | 93 | 99 | 88 | 107 | 146 | 198 |
| CFO/OP | 79% | 106% | 113% | 108% | 104% | 122% | 92% | 72% | 128% | 141% | 123% | 104% |
Ratios
Consolidated / View Standalone
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 10 | 11 | 8 | 10 | 11 | 14 | 33 | 58 | 59 | 28 | 39 | 33 |
| Inventory Days | 48 | 56 | 65 | 66 | 60 | 64 | 52 | 53 | 62 | 104 | 89 | 81 |
| Days Payable | 5 | 10 | 6 | 25 | 25 | 68 | 56 | 36 | 54 | 88 | 146 | 109 |
| Cash Conversion Cycle | 53 | 57 | 67 | 50 | 46 | 10 | 29 | 75 | 67 | 44 | -18 | 4 |
| Working Capital Days | 28 | 2 | 19 | 10 | 28 | -8 | 19 | 41 | 31 | 7 | 13 | 19 |
| ROCE % | 24% | 28% | 33% | 30% | 35% | 36% | 42% | 17% | 18% | 25% | 35% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tests Conducted Million |
|
|||||||||||
| Patients Served Million |
||||||||||||
| Quarterly Active Franchisees count |
||||||||||||
| Number of Labs (India) count |
||||||||||||
| Average Turnaround Time hours |
||||||||||||
| Revenue per Test INR |
||||||||||||
| Tests per Patient count |
||||||||||||
| Complaints per Million Tests count |
||||||||||||
Extracted by Screener AI
Documents
Announcements
- Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
-
Grant Of Employee Stock Options Under Thyrocare Employee Stock Option Scheme.
- Thyrocare granted 1,92,000 ESOPs at Rs. 10 each on September 24, 2026.
-
Closure of Trading Window
- Trading window closes from October 1, 2026 until 48 hours after Q2 FY2026 results.
-
Sale Of The Entire Shareholding Held By The Company In Nueclear Healthcare Limited (A Material Wholly Owned Subsidiary), Subject To The Approval Of The Shareholders Of The Company
- Board approved sale of 100% NHL stake for Rs 141.4 crore, plus property purchase for Rs 20.59 crore.
-
Announcement under Regulation 30 (LODR)-Acquisition
- Board approves sale of 100% Nueclear Healthcare for Rs141.4 crore, plus property purchase and Trovera CCPS acquisition.
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
Concalls
-
Jul 2026Transcript PPT REC
-
May 2026Transcript PPT
-
Feb 2026Transcript PPT REC
-
Oct 2025Transcript PPT
-
Jul 2025Transcript PPT REC
-
Apr 2025Transcript PPT REC
-
Jan 2025Transcript PPT
-
Oct 2024Transcript PPT
-
Jul 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022PPT
-
Nov 2021PPT
-
Aug 2021PPT
-
May 2021PPT
-
Feb 2021Transcript PPT
-
Nov 2020Transcript PPT
-
Jul 2020PPT
-
May 2020PPT
-
Feb 2020PPT
-
Nov 2019PPT
-
Aug 2019PPT
-
Jun 2019Transcript
-
May 2019PPT
-
Feb 2019Transcript PPT
-
Nov 2018Transcript PPT
-
Aug 2018Transcript PPT
-
May 2018Transcript PPT
-
Feb 2018Transcript PPT
-
Dec 2017Transcript PPT
Business Segments
1) Diagnostic Testing Services (92% in FY25 vs 94% in FY22): [1] [2] The company is one of the leading Pan-India diagnostic chains, offering a range of tests focused on early disease detection and health management. It provides 929 tests and 288 profiles, including 43 wellness packages under the “Aarogyam” brand. It processes 3 Bn investigations annually and can process 10 Bn annually. [3] [4]